Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Phase 2; no discontinuation disclosed.
WVE-006
Phase 2 · Active
Target SERPINA1
Partnerships GSK (license terminated; Wave retains the asset)
Indications
alpha-1 antitrypsin deficiency (AATD)(Phase 2)
Status note GSK license terminated; Wave continues development; no discontinuation disclosed.
WVE-008
Preclinical · Active
Target PNPLA3
Indications
liver disease(Preclinical)
Status note Preclinical; no discontinuation disclosed.
WVE-N531
Phase 2 · Active
Target dystrophin exon 53
Indications
Duchenne muscular dystrophy (DMD)(Phase 2)
Status note Phase 2; no discontinuation disclosed.
WVE-003
Phase 2 · Active
Target HTT
Indications
Huntington's disease(Phase 2)
Status note Phase 2; no discontinuation disclosed.
Per-asset detail extracted from the 10-Q filed 2026-07-30. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.